154 Matching Annotations
  1. Oct 2021
  2. Sep 2021
  3. Aug 2021
    1. Madhi, S. A., Koen, A. L., Izu, A., Fairlie, L., Cutland, C. L., Baillie, V., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., Briner, C., Aley, P. K., Bhikha, S., Hermanus, T., Horne, E., Jose, A., Kgagudi, P., Lambe, T., Masenya, M., … Kwatra, G. (2021). Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: An interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. The Lancet HIV, 0(0). https://doi.org/10.1016/S2352-3018(21)00157-0

  4. Jul 2021
  5. Jun 2021
  6. May 2021
    1. Gobeil, P., Pillet, S., Séguin, A., Boulay, I., Mahmood, A., Vinh, D. C., Charland, N., Boutet, P., Roman, F., Most, R. V. D., Perez, M. de los A. C., Ward, B. J., & Landry, N. (2021). Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older. MedRxiv, 2021.05.14.21257248. https://doi.org/10.1101/2021.05.14.21257248

    1. Eric Topol. (2021, February 17). New reports @NEJM today confirming some immune evasion of the B.1.351 variant (identified in South Africa) to both the mRNA vaccines, in vitro data @BioNTech_Group/@Pfizer and @moderna_tx. Less vaccine efficacy vs B.1.351 has been confirmed in clinical trials for 3 vaccines https://t.co/2N7eKDllso [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1362160675913568256

    1. Dron, L., Taljaard, M., Cheung, Y. B., Grais, R., Ford, N., Thorlund, K., Jahan, F., Nakimuli-Mpungu, E., Xavier, D., Bhutta, Z. A., Park, J. J. H., & Mills, E. J. (2021). The role and challenges of cluster randomised trials for global health. The Lancet Global Health, 9(5), e701–e710. https://doi.org/10.1016/S2214-109X(20)30541-6

    1. The Lancet. (2021, April 16). Quantity > quality? The magnitude of #COVID19 research of questionable methodological quality reveals an urgent need to optimise clinical trial research—But how? A new @LancetGH Series discusses challenges and solutions. Read https://t.co/z4SluR3yuh 1/5 https://t.co/94RRVT0qhF [Tweet]. @TheLancet. https://twitter.com/TheLancet/status/1383027527233515520

    1. Park, J. J. H., Grais, R. F., Taljaard, M., Nakimuli-Mpungu, E., Jehan, F., Nachega, J. B., Ford, N., Xavier, D., Kengne, A. P., Ashorn, P., Socias, M. E., Bhutta, Z. A., & Mills, E. J. (2021). Urgently seeking efficiency and sustainability of clinical trials in global health. The Lancet Global Health, 9(5), e681–e690. https://doi.org/10.1016/S2214-109X(20)30539-8

  7. Apr 2021
  8. Mar 2021
    1. Rosendaal, F. R. (2020). Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949. International Journal of Antimicrobial Agents, 106063. https://doi.org/10.1016/j.ijantimicag.2020.106063

    1. Yufika, A., Wagner, A. L., Nawawi, Y., Wahyuniati, N., Anwar, S., Yusri, F., Haryanti, N., Wijayanti, N. P., Rizal, R., Fitriani, D., Maulida, N. F., Syahriza, M., Ikram, I., Fandoko, T. P., Syahadah, M., Asrizal, F. W., Aletta, A., Haryanto, S., Jamil, K. F., … Harapan, H. (2020). Parents’ hesitancy towards vaccination in Indonesia: A cross-sectional study in Indonesia. Vaccine, 38(11), 2592–2599. https://doi.org/10.1016/j.vaccine.2020.01.072

    1. Meng Z , Wang T , Li C  et al.   PREPRINT: An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area. medRxiv  2020:2020.04.11.20061473. doi:10.1101/2020.04.11.20061473.
    1. Meng Z , Wang T , Li C  et al.   PREPRINT: An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area. medRxiv  2020:2020.04.11.20061473.
  9. Feb 2021
    1. Dr Ellie Murray. (2020, December 3). Some really great resources & discussions in this thread. The tl;dr is (1) yes, the vaccine trials included some people who had previously had COVID; and (2) in general vaccination plans will include those who have previously been sick/infected. Thanks all! [Tweet]. @EpiEllie. https://twitter.com/EpiEllie/status/1334545373126389766

    1. Carl T. Bergstrom. (2020, December 5). I don’t have a background in medical ethics but this makes me uncomfortable unless it was very clearly explained to study participants at enrollment, and to some degree even then. H/t @RMCarpiano https://t.co/WUE1mXgjJG https://t.co/yLXkxIa5O8 [Tweet]. @CT_Bergstrom. https://twitter.com/CT_Bergstrom/status/1335152266840424449

  10. Jan 2021
    1. それを実践しているのが、全国に200店舗以上の大型スーパーマーケット「TRIAL」を展開するトライアルホールディングスだ

      TRIALはいつも先進技術に積極的に取り込んでいる

    1. Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., Berghmans, P.-J., Kimmel, M., Van Damme, P., de Hoon, J., Smith, W., Stephenson, K. E., De Rosa, S. C., Cohen, K. W., McElrath, M. J., … Schuitemaker, H. (2021). Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2034201

  11. Dec 2020
    1. Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … Zuidewind, P. (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)32661-1

  12. Nov 2020
    1. “Let’s say a trial is listed and I have to cross examine a witness,” he said. “Now, what is the guarantee that the witness would be willing to go all the way to the court in such a time?” If witnesses do not appear, then the matter would merely be adjourned.

      access to justice